Bracco’s VueJect contrast system secures FDA and Health Canada approvals
August 12, 2026
The device will be sold initially in the US and Canada, with further submissions planned in additional markets.
The device will be sold initially in the US and Canada, with further submissions planned in additional markets.
Wandercraft, a Paris-based robotics company, announced that the FDA has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility.
FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
MILAN, Aug. 11, 2026 /PRNewswire/ — Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to support cardiology imaging specifically, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and authorization from Health Canada.
HOUSTON, Aug. 11, 2026 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.” The patent describes methods utilizing fibroblasts to improve the engraftment and long-term function of transplanted pancreatic islets, addressing one of the major challenges in islet transplantation.
BEIJING, Aug. 11, 2026 /PRNewswire/ — Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) (“Datasea” or the “Company”), a technology company focused on acoustic high-tech and AI multimodal digital solutions, today announced that Shuhai Jingwei (Shenzhen) Information Technology Co., Ltd. (“Shuhai Jingwei”), the Company’s variable interest entity in China, has completed establishment registration and device listing with the U.S. Food and Drug Administration (“FDA”) for its NeuroVibe Biofeedback System, including products NV-02 and NV-03.
For decades, neuroscientists have been able to record which parts of the brain show increased electrical activity during a behavior, such as when we form a memory or make a decision. But scientists haven’t been able to determine how those regions are communicating with and influencing one another, nor identify which regions serve as the main orchestrators.
Long-term diabetes management requires continuous blood glucose monitoring to detect abnormalities early and intervene in time. However, conventional fingertip blood sampling is both painful and inconvenient, while most continuous glucose monitoring (CGM) products currently available on the market rely on biological enzymes—requiring regular replacement, incurring higher costs and demanding stringent storage conditions.
The skin is the body’s largest organ. It is a protective shield that keeps harmful pathogens out and vital fluids inside. These very properties make it a tough engineering challenge to design wearable health sensors because many internal chemical signals cannot easily pass through it.
Multiple sclerosis (MS) is the most common chronic autoimmune disease of the central nervous system. An early and accurate diagnosis is crucial for improving the effectiveness of treatment and reducing nerve damage.